Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors.

Abstract

Patients with advanced cancer, previously treated with immune checkpoint blockade therapy, may retain residual treatment when undergoing the initial infusion of experimental monotherapy in phase 1 clinical trials. ANV419, an antibody-cytokine fusion protein, combines interleukin-2 (IL-2) with an anti-IL-2 monoclonal antibody, aiming to stimulate the expansion of CD8 T and natural killer lymphocytes while restricting regulatory T lymphocytes. In the recent publication of the phase 1 dose escalation study of ANV419, a notable gap exists in detailed information regarding patients' prior antitumoral treatments, specifically programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) targeted monoclonal antibodies. Some patients likely retained residual anti-PD-1/PD-L1 monoclonal antibodies, potentially influencing the outcomes of ANV419. In a separate clinical cohort, we retrospectively measured the residual concentration of nivolumab and pembrolizumab, revealing persistent serum concentrations of anti-PD-1/PD-L1 antibodies even months after treatment cessation. This underscores the importance of comprehensively documenting prior immunotherapy details in clinical trials. Such information is crucial for understanding potential interactions that may impact both immunological and clinical effects.

• Authors: Laurent Mathiot, David Combarel, Justin Cagnat, Julia Delahousse, Kaissa Ouali, Aurelien Marabelle, Yohann Loriot, Santiago Ponce, Stephane Champiat, Sophie Broutin, Francois-Xavier Danlos
• Journal: Journal for immunotherapy of cancer (J Immunother Cancer) Vol. 12 Issue 5 (May 03 2024) ISSN: 2051-1426 [Electronic] England
• PMID: 38702147 (Publication Type: Journal Article, Clinical Trial, Phase I, Research Support, Non-U.S. Gov't)
• Copyright: © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Chemical References

• Interleukin-2
• Antibodies, Monoclonal, Humanized
• Immune Checkpoint Inhibitors
• Recombinant Fusion Proteins

Topics

• Humans
• Neoplasms (drug therapy, immunology)
• Male
• Female
• Middle Aged
• Aged
• Interleukin-2 (therapeutic use, administration & dosage)
• Antibodies, Monoclonal, Humanized (therapeutic use, administration & dosage)
• Immune Checkpoint Inhibitors (therapeutic use, pharmacology, administration & dosage)
• Adult
• Recombinant Fusion Proteins (therapeutic use, administration & dosage)